하이텍팜

106190KOSDAQ

55.5 / 100

Reference Date: 2026-09-08

Financial Score30.0 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 8.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hitek Pharm is a specialized pharmaceutical company established in 1998, focusing on carbapenem-class antibiotic APIs. Its flagship products, imipenem and ertapenem, leverage strong antibacterial properties and high price competitiveness, with exports accounting for 99.99% of sales, primarily to Europe and Asia. In 2023, the company achieved sales of 77.5 billion KRW and operating profit of 15.56 billion KRW, demonstrating sustained growth.

Number of Employees

130people

Average Salary

59.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.68Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

0.85Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

9.17Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

0.39Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼4.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.4% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.7% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 10,440Won52-week high 25,00052-week low 9,960

1-month return1.0Point

1m -8.18% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral반기보고서 (2026.06)2026-08-14
Neutral[기재정정]반기보고서 (2026.06)2026-08-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-12
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-12
Neutral주식등의대량보유상황보고서(일반)2026-08-12